Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation Press Release / March 30, 2022March 6, 2025
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich’s Ataxia Press Release / March 28, 2022March 7, 2025
Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022) Press Release / March 24, 2022March 6, 2025
Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration Press Release / March 17, 2022March 6, 2025
Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical Scientific Conference Press Release / March 16, 2022March 6, 2025
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit Press Release / February 22, 2022March 6, 2025
Last Patient Completes Treatment in Stealth BioTherapeutics’ Phase 2 Geographic Atrophy Clinical Trial Press Release / February 15, 2022March 7, 2025
Stealth BioTherapeutics Announces Oral Presentation of New Duchenne Muscular Dystrophy Data at the 2022 Muscular Dystrophy Association Clinical and Scientific Conference Press Release / February 8, 2022March 6, 2025
